INCYTE CORP — Director's Dealing 2025

Jan 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INCYTE CORP (INCY)
CIK: 0000879169
Period of Report: 2025-01-06

Reporting Person: Issa Mohamed Khairie (EVP, Head of US Oncology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-06	Common Stock	A	48671	—	Acquired	48671	Direct

Footnotes

F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Includes the January 6, 2025 aggregate grant of 48,671 shares of common stock.